Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness |
| |
Authors: | J Stephenne |
| |
Institution: | Vaccines Research & Development, Smith Kline Biologicals, Rixensart, Belgium. |
| |
Abstract: | Any attempt to reduce the incidence of hepatitis B on a worldwide scale requires the availability of large quantities of potent, safe and affordable hepatitis B vaccine. However, ongoing doubts or concerns--justified or not--persist about the comparative safety, immunogenicity and cost-effectiveness of commercially available hepatitis B vaccines, whether derived from plasma or produced via recombinant expression systems. This review compares plasma versus recombinant hepatitis B vaccines in terms of these alleged differences and in the light of increasing clinical data acquired following administration of recombinant yeast-derived hepatitis B vaccines. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|